µ¼Ê¦ÐÕÃû£º¹ùС¿É
ÐÔ±ð£ºÅ®
ÈËÆøÖ¸Êý£º106
ËùÊôԺУ£ºÖйúÒ©¿Æ´óѧ
ËùÊôԺϵ£ºÒ©Ñ§Ôº
Ö°³Æ£º¸±½ÌÊÚ
µ¼Ê¦ÀàÐÍ£ºË¶µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÒ©Îﻯѧ
Ñо¿ÁìÓò£º ÉúÎï»îÐÔ·Ö×ÓµÄÉè¼ÆÓëºÏ³É
Ñо¿ÁìÓò£º ÉúÎï»îÐÔ·Ö×ÓµÄÉè¼ÆÓëºÏ³É [ÊÕÆð]
¸öÈ˼òÊö :
2017ÄêҩѧԺ¡°ÉÁÒ©¿ÎÌá±ÇàÄê½Ìʦ½²¿Î±ÈÈüµÚÒ»Ãû¡£
¿ÆÑй¤×÷ :
´ú±íÐÔÂÛÖø£º1.Dong-Dong Li, Wei-Lin Chen, Zhi-Hui Wang, Yi-Yue Xie, Xiao-Li Xu, Zheng-Yu Jiang, Xiao-Jin Zhang, Qi-Dong You*, Xiao-Ke Guo*, High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity, Eur. J. Med. Chem., 2016, 124, 480-489.2.Dong-Dong Li, Zhi-Hui Wang, Wei-Lin Chen, Yi-Yue Xie, Qi-Dong You*, Xiao-Ke Guo*, Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction, Bioorg. Med. Chem., 2016, 24, 6109-6118.3.Wei-Lin Chen, Zhi-Hui Wang, Tao-Tao Feng, Dong-Dong Li, Chu-Hui Wang, Xiao-Li Xu, Xiao-Jin Zhang, Qi-Dong You*, Xiao-Ke Guo*, Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification, Bioorg. Med. Chem., 2016, 24, 6102-61084.Xiao-Ke Guo, Wei-Lin Chen, Hao-Peng Sun*, Qi-Dong You*, Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity, Curr. Top. Med. Chem., 2016, 16, 1843-1854.5.Tao-Tao Feng, Dong-Dong Li, Hai Wang, Jian Zhuang, Fang Liu, Qichao Bao, Yonghua Lei, Wei-Lin Chen, Xiao-Jin Zhan, Xiao-Li Xu, Hao-Peng Sun, Qi-Dong You*, Xiao-Ke Guo*, Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: Introduction of an additional carboxyl group at the C-2 position of quinoline, Eur. J. Med. Chem., 2015, 105, 145-155.6.Tao-Tao Feng, Wei-Lin Chen, Dong-Dong Li, Hong-Zhi Lin, Fang Liu, Qichao Bao, Yong-Hua Lei, Xiao-Jin Zhang, Xiao-Li Xu, Xiao-Ke Guo*, Qidong You*, Haopeng Sun*, Identification of novel JMJD2A inhibitor scaffold using shape and electrostatic similarity search combined with docking method and MM-GBSA approach, RSC Adv., 2015, 5, 82936-82946.7.Xiao-Ke Guo, Xiang-Lei Ma, Qian Yang, Jing Xu, Lu Huang, Jian-Min Jia, Jiao-Jiao Shan, Li Liu, Wei-Lin Chen, Hong-Xi Chu, Jin-Lian Wei, Xiao-Jin Zhang, Hao-Peng Sun*, Yi-Qun Tang*, Qi-Dong You*, Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I). Eur J Med Chem, 2014, 81, 89-94.8.Xiao-Ke Guo, Hao-Peng Sun*, Lv-Pei Du, Lu Huang, Jing Xu, Ying-Ying Zhu, Peng Yu, Xiao-Jin Zhang, Yi-Qun Tang* and Qi-Dong You*, Discovery of Aroyl Piperazine Derivatives as IKr & IKs Dual Inhibitors for Cardiac Arrhythmia Treatment, Med. Chem., 2014, 10, 497-505.
½ÌÓý±³¾° :
2009Äê7Ô±ÏÒµÓÚÖйúÒ©¿Æ´óѧ»ù´¡Ò©Ñ§Àí¿Æ»ùµØ°àöλÔÓéÀֵǼÈë¿ÚÏÂÔØ»ñÀíѧѧʿѧ룬±¾¿Æ±ÏÒµºóÃâÍÆÎªÖйúÒ©¿Æ´óѧҩÎﻯѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØË¶²©Á¬¶ÁÑо¿Éú£¬2014Äê6Ô»ñÀíѧ²©Ê¿Ñ§Î»¡£
ÖйúÒ©¿Æ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-¹ùС¿É
±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø/2019-05-27
Ïà¹Ø»°Ìâ/Éè¼Æ Ò©Îﻯѧ ÉúÎï Àíѧ ÖйúÒ©¿Æ´óѧ
ÖйúÒ©¿Æ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-»ôÃÀÈØ
µ¼Ê¦ÐÕÃû£º»ôÃÀÈØÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º104ËùÊôԺУ£ºÖйúÒ©¿Æ´óѧËùÊôԺϵ£ºÒ©Ñ§ÔºÖ°³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÒ©¼Áѧ¡¢Ò©Ñ§£¨¹¤ÒµÒ©Ñ§·½Ïò£©Ñо¿ÁìÓò£ºÐ¼ÁÐͺÍм¼Êõ¡£Ñо¿ÁìÓò£ºÐ¼ÁÐͺÍм¼Êõ¡£[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£ºhuomeirongcpu@163.com¸öÈ˼òÊö:»ôÃÀÈØ£¬Å®£¬Ò©¼Áѧ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Ö£Öݺ½¿Õ¹¤Òµ¹ÜÀíѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÁõÓÀÀö
µ¼Ê¦ÐÕÃû£ºÁõÓÀÀöÐÔ±ð£ºÈËÆøÖ¸Êý£º104ËùÊôԺУ£ºÖ£Öݺ½¿Õ¹¤Òµ¹ÜÀíѧԺËùÊôԺϵ£º»á¼ÆÑ§ÔºÖ°³Æ£º¸±½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÑо¿ÁìÓò£º»á¼ÆÀíÂÛÓëʵÎñ/¹ÜÀí»á¼ÆÊ¦·½ÏòÑо¿ÁìÓò£º»á¼ÆÀíÂÛÓëʵÎñ/¹ÜÀí»á¼ÆÊ¦·½Ïò[ÊÕÆð] ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖйúÒ©¿Æ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÉòÎÀÑô
µ¼Ê¦ÐÕÃû£ºÉòÎÀÑôÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º103ËùÊôԺУ£ºÖйúÒ©¿Æ´óѧËùÊôԺϵ£ºÀíѧԺְ³Æ£º¸±½ÌÊÚµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÒ©Îï·ÖÎöѧͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£ºshenweiyang@cpu.edu.cn¸öÈ˼òÊö:ÉòÎÀÑô£¬ÄУ¬²©Ê¿£¬¸±½ÌÊÚ£¬ÏÖΪҩÎï·ÖÎöѧ¡¢»¯Ñ§öλÔÓéÀֵǼÈë¿ÚÏÂÔØÑ§ÊõѧλÓ빤ҵҩѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØÑ§Î»Ë¶Ê¿Éúµ¼Ê¦£¬ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖйúÒ©¿Æ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-¶¡æ«
µ¼Ê¦ÐÕÃû£º¶¡æ«ÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º103ËùÊôԺУ£ºÖйúÒ©¿Æ´óѧËùÊôԺϵ£ºÒ©Ñ§ÔºÖ°³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£º²©µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÒ©Îï·ÖÎöѧ¡¢Ò©Ñ§£¨¹¤ÒµÒ©Ñ§·½Ïò£©Ñо¿ÁìÓò£ºÒ©Îï·ÖÎöвÄÁϺÍм¼Êõ£»¼²²¡Õï¶Ï̽Õ룻¹âÆ×¼¼ÊõÔÚÒ©Îï·ÖÎöÖеÄÓ¦Óá£Ñо¿ÁìÓò£ºÒ©Îï·ÖÎöвÄÁϺÍм¼Êõ£»¼²²¡Õï¶Ï̽Õ룻¹âÆ×¼¼ÊõÔÚÒ©Îï·ÖÎöÖеÄÓ¦Óá£[ÊÕÆð ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Ö£Öݺ½¿Õ¹¤Òµ¹ÜÀíѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-Ñî¹ã¾ü
µ¼Ê¦ÐÕÃû£ºÑî¹ã¾üÐÔ±ð£ºÈËÆøÖ¸Êý£º103ËùÊôԺУ£ºÖ£Öݺ½¿Õ¹¤Òµ¹ÜÀíѧԺËùÊôԺϵ£ºÍÁľ½¨Öþ¹¤³ÌѧԺְ³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÑо¿ÁìÓò£º½ÚÄÜ»·±£¹¤³Ì²ÄÁÏ£»½¨Öþ²úÒµÏÖ´ú»¯£»º£Ãà³ÇÊÐÓë³ÇÊеØÏÂ×ۺϹÜÀÈÑо¿ÁìÓò£º½ÚÄÜ»·±£¹¤³Ì²ÄÁÏ£»½¨Öþ²úÒµÏÖ´ú»¯£»º£Ãà³ÇÊÐÓë³ÇÊеØÏÂ×ۺϹÜÀÈ[ÊÕÆð]¸öÈ˼òÊö:Ñî¹ã¾ü£¬ÄУ¬ºÓ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖйúÒ©¿Æ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÔÀÍñÇç
µ¼Ê¦ÐÕÃû£ºÔÀÍñÇçÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º103ËùÊôԺУ£ºÖйúÒ©¿Æ´óѧËùÊôԺϵ£ºÀíѧԺְ³Æ£º¸±Ñо¿Ô±µ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º»¯Ñ§Ñо¿ÁìÓò£º1.Éè¼ÆºÍ¿ª·¢¸ßͨÁ¿Î¢Á÷¿ØÐ¾Æ¬ÓÃÓÚÁÙ´²Õï¶ÏºÍÒ©Îïɸѡ£»2.¿ª·¢»ùÓÚÄÉÃײÄÁϺÍ΢Á÷¿ØÐ¾Æ¬µÄÉú...[Õ¹¿ª]Ñо¿ÁìÓò£º1.Éè¼ÆºÍ¿ª·¢¸ßͨÁ¿Î¢Á÷¿ØÐ¾Æ¬ÓÃÓÚÁÙ´²Õï¶ÏºÍÒ©Îïɸѡ£»2 ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖйúÒ©¿Æ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-κ־·ï
µ¼Ê¦ÐÕÃû£ºÎºÖ¾·ïÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º103ËùÊôԺУ£ºÖйúÒ©¿Æ´óѧËùÊôԺϵ£ºÖÐҩѧԺְ³Æ£º¸±½ÌÊÚµ¼Ê¦ÀàÐÍ£º²©µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÖÐҩѧ£¨ÖÐÒ©Ò©Àíѧ£©Ñо¿ÁìÓò£ºÖÐÒ©¿¹Ñ×ÃâÒßÒ©ÀíѧÑо¿ÁìÓò£ºÖÐÒ©¿¹Ñ×ÃâÒßÒ©Àíѧ[ÊÕÆð]ͨѶ·½Ê½:µç×ÓÓʼþ£ºzhifeng-wei@hotmail.com¸öÈ˼òÊö:κ־·ï£¬Å®£¬ÖÐҩѧ²©Ê¿£¨ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖйúÒ©¿Æ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ñ¼½à
µ¼Ê¦ÐÕÃû£ºñ¼½àÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º102ËùÊôԺУ£ºÖйúÒ©¿Æ´óѧËùÊôԺϵ£ºÉúÃü¿ÆÑ§Óë¼¼ÊõѧԺְ³Æ£º¸±½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÎ¢ÉúÎïÓëÉú»¯Ò©Ñ§Ñо¿ÁìÓò£º¿¹²¡¶¾¿¹Ö×ÁöÒ©ÎïµÄҩЧÓë»úÖÆÑо¿¡¢²¡¶¾ÃâÒßÓëÖ×ÁöÃâÒßµÈÁìÓò¡£Ñо¿ÁìÓò£º¿¹²¡¶¾¿¹Ö×ÁöÒ©ÎïµÄҩЧÓë»úÖÆÑо¿¡¢²¡¶¾ÃâÒßÓëÖ×ÁöÃâÒßµÈÁìÓò¡£[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖйúÒ©¿Æ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-å§Éç°à
µ¼Ê¦ÐÕÃû£ºå§Éç°àÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º103ËùÊôԺУ£ºÖйúÒ©¿Æ´óѧËùÊôԺϵ£ºÖÐҩѧԺְ³Æ£º¸±Ñо¿Ô±µ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÉúҩѧ¡¢ÖÐҩѧ£¨ÖÐÒ©×ÊԴѧ£©Ñо¿ÁìÓò£º£¨1£©Éúҩѧ¿ÆÒ©ÓÃÖ²ÎïÖÖÖÊ×ÊÔ´¼°ÆäÖÊÁ¿ÆÀ¼Û£»£¨2£©ÖÐÒ©×ÊԴѧ¿ÆÖÐÒ©×ÊÔ´ÓëÖÊÁ¿¼°Æä·Ö×Ó»úÀíÑÐ...[Õ¹¿ª]Ñо¿ÁìÓò£º£¨1£©Éúҩѧ¿ÆÒ©ÓÃÖ²ÎïÖÖÖÊ×ÊÔ´ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖйúÒ©¿Æ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-½ª»¢ÁÖ
µ¼Ê¦ÐÕÃû£º½ª»¢ÁÖÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º102ËùÊôԺУ£ºÖйúÒ©¿Æ´óѧËùÊôԺϵ£ºÒ©Ñ§ÔºÖ°³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÒ©¼Áѧ¡¢Ò©Ñ§£¨¹¤ÒµÒ©Ñ§·½Ïò£©Ñо¿ÁìÓò£ºBiomedicalPolymer-basedDrugDelivery,GeneThera...[Õ¹¿ª]Ñо¿ÁìÓò£ºBiomedicalPolymer-ba ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖйúÒ©¿Æ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÅíêÍ
µ¼Ê¦ÐÕÃû£ºÅíêÍÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º102ËùÊôԺУ£ºÖйúÒ©¿Æ´óѧËùÊôԺϵ£ºÒ©Ñ§ÔºÖ°³Æ£ºÑо¿Ô±µ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÒ©Ñ§£¨¹¤ÒµÒ©Ñ§·½Ïò£©Ñо¿ÁìÓò£º£¨1£©¿¹Ö×ÁöÒ©ÎïµÄÐÂÒ©Éè¼ÆÓë»îÐÔÆÀ¼Û£»£¨2£©Ö×ÁöÄÍÒ©·Ö×ÓÍøÂç»úÖÆ¼°¿Ë·þвßÂÔ£»£¨3£©»·¾³Óë...[Õ¹¿ª]Ñо¿ÁìÓò£º£¨1£©¿¹Ö×ÁöÒ©ÎïµÄÐÂÒ©Éè¼ÆÓë»îÐÔÆÀ¼Û£»£¨2£© ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖйúÒ©¿Æ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-¼¾Ò»±ø
µ¼Ê¦ÐÕÃû£º¼¾Ò»±øÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º100ËùÊôԺУ£ºÖйúÒ©¿Æ´óѧËùÊôԺϵ£ºÀíѧԺְ³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£º²©µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÒ©Îï·ÖÎöѧÑо¿ÁìÓò£ºÎªÃ«Ï¸¹ÜµçÓ¾ÓëÓ¦Óã»ÊÖÐÔÒ©Îï·ÖÀë·ÖÎö£»Î¢Á÷¿Ø¼¼ÊõÓëÓ¦Óã»ÐÂÒ©ÖÊÁ¿¿ØÖÆÑо¿¡£Ñо¿ÁìÓò£ºÎªÃ«Ï¸¹ÜµçÓ¾ÓëÓ¦Óã»ÊÖÐÔÒ©Îï·ÖÀë·ÖÎö£»Î¢Á÷¿Ø¼¼ÊõÓëÓ¦Óã»ÐÂÒ©ÖÊÁ¿¿ØÖÆÑо¿¡£[ÊÕÆð]ͨ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Ö£Öݺ½¿Õ¹¤Òµ¹ÜÀíѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-κÓÀ»Ô
µ¼Ê¦ÐÕÃû£ºÎºÓÀ»ÔÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º100ËùÊôԺУ£ºÖ£Öݺ½¿Õ¹¤Òµ¹ÜÀíѧԺËùÊôԺϵ£º»úµç¹¤³ÌѧԺְ³Æ£º½²Ê¦µ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÑо¿ÁìÓò£º²ÄÁϼӹ¤Óë¿É¿¿ÐÔÆÀ¹ÀÑо¿ÁìÓò£º²ÄÁϼӹ¤Óë¿É¿¿ÐÔÆÀ¹À[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£ºyangguangwyh@126.com¸öÈ˼òÊö:κÓÀ»Ô£¬ÄУ¬1979ÄêÉú£¬ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖйúÒ©¿Æ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-Îâ½à
µ¼Ê¦ÐÕÃû£ºÎâ½àÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º101ËùÊôԺУ£ºÖйúÒ©¿Æ´óѧËùÊôԺϵ£ºÉúÃü¿ÆÑ§Óë¼¼ÊõѧԺְ³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£º²©µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÎ¢ÉúÎïÓëÉú»¯Ò©Ñ§¡¢ÉúÎïѧͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£ºwujie@cpu.edu.cn¸öÈ˼òÊö:Îâ½à£¬½ÌÊÚ£¬²©Ê¿Éúµ¼Ê¦¡£2004Äê»ñ΢ÉúÎïÓëÉú»¯Ò©Ñ§²©Ê¿Ñ§Î»¡£2008-201 ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖйúÒ©¿Æ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-Áõ¶«·É
µ¼Ê¦ÐÕÃû£ºÁõ¶«·ÉÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º99ËùÊôԺУ£ºÖйúÒ©¿Æ´óѧËùÊôԺϵ£ºÒ©Ñ§ÔºÖ°³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£º²©µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÒ©¼ÁѧÑо¿ÁìÓò£º1)¸ßͨÁ¿ÖƱ¸³¬¸ßÔØÒ©ÇÒÒ©Îï¿É¿ØÊͷŵĵÝËÍϵͳ2)¿É¹¤Òµ»¯·Å´óµÄÒ©ÎïÔØÌåÖÆ±¸¼¼Êõ¼°ÆäÉ豸µÄ...[Õ¹¿ª]Ñо¿ÁìÓò£º1)¸ßͨÁ¿ÖƱ¸³¬¸ßÔØÒ©ÇÒÒ©Îï¿É¿ØÊͷŵĵÝËÍϵͳ2)¿É¹¤Òµ»¯·Å ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27
